Cell culture metabolomics in the diagnosis of lung cancer—the influence of cell culture conditions

Lung cancer is the leading cause of cancer deaths. Unfortunately, lung cancer is often diagnosed only when it becomes symptomatic or at an advanced stage when few treatment options are available. Hence, a diagnostic test suitable for screening widespread populations is required to enable earlier diagnosis. Analysis of exhaled breath provides a non-invasive method for early detection of lung cancer. Analysis of volatile organic compounds (VOCs) by various mass spectral techniques has identified potential biomarkers of disease. Nevertheless, the metabolic origins and the disease specificity of VOCs need further elucidation. Cell culture metabolomics can be used as a bottom-up approach to identify biomarkers of pathological conditions and can also be used to study the metabolic pathways that produce such compounds. This paper summarizes the current knowledge of lung cancer biomarkers in exhaled breath and emphasizes the critical role of cell culture conditions in determining the VOCs produced in vitro. Hypoxic culture conditions more closely mimic the conditions of cancer cell growth in vivo. We propose that since hypoxia influences cell metabolism and so potentially the VOCs that the cancer cells produce, the cell culture metabolomics projects should consider culturing cancer cells in hypoxic conditions.

[1]  Konrad Schwarz,et al.  Compounds enhanced in a mass spectrometric profile of smokers' exhaled breath versus non-smokers as determined in a pilot study using PTR-MS , 2008, Journal of breath research.

[2]  Anton Amann,et al.  TD-GC-MS Analysis of Volatile Metabolites of Human Lung Cancer and Normal Cells In vitro , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[3]  P. Španěl,et al.  The challenge of breath analysis for clinical diagnosis and therapeutic monitoring. , 2007, The Analyst.

[4]  Ulrike Tisch,et al.  Volatile Organic Compounds in Exhaled Breath as Biomarkers for the Early Detection and Screening of Lung Cancer , 2012 .

[5]  Kevin Gleeson,et al.  Detection of lung cancer with volatile markers in the breath. , 2003, Chest.

[6]  W. Miekisch,et al.  Breath gas aldehydes as biomarkers of lung cancer , 2009, International journal of cancer.

[7]  H. Issaq,et al.  Promotion of mouse lung tumors by bioaccumulated polychlorinated aromatic hydrocarbons. , 1991, Experimental lung research.

[8]  Tomas Mikoviny,et al.  Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro , 2008, Cancer Cell International.

[9]  Stephen S. Hecht,et al.  Approaches to Cancer Prevention Based on an Understanding of N-Nitrosamine Carcinogenesis , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[10]  Philip Hahnfeldt,et al.  Cancer: looking outside the genome , 2000, Nature Reviews Molecular Cell Biology.

[11]  X. Zhang,et al.  Investigation of volatile biomarkers in lung cancer blood using solid-phase microextraction and capillary gas chromatography-mass spectrometry. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  W. Miekisch,et al.  Diagnostic potential of breath analysis--focus on volatile organic compounds. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[13]  M. Takino,et al.  Analysis of volatile sulphur compounds in breath by gas chromatography-mass spectrometry using a three-stage cryogenic trapping preconcentration system. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[14]  C. Kneepkens,et al.  The hydrocarbon breath test in the study of lipid peroxidation: principles and practice. , 1992, Clinical and investigative medicine. Medecine clinique et experimentale.

[15]  M. Mehrali,et al.  A review on powder-based additive manufacturing for tissue engineering: selective laser sintering and inkjet 3D printing , 2015, Science and technology of advanced materials.

[16]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[17]  J W Dallinga,et al.  A profile of volatile organic compounds in breath discriminates COPD patients from controls. , 2009, Respiratory medicine.

[18]  P. Boyle,et al.  Diet and oxidative stress in breast, colon and prostate cancer patients: a case-control study. , 1994, European journal of clinical nutrition.

[19]  Hossam Haick,et al.  Volatile organic compounds of lung cancer and possible biochemical pathways. , 2012, Chemical reviews.

[20]  C. Kneepkens,et al.  The potential of the hydrocarbon breath test as a measure of lipid peroxidation. , 1994, Free radical biology & medicine.

[21]  A. Hauschild,et al.  Integrated statistical learning of metabolic ion mobility spectrometry profiles for pulmonary disease identification. , 2012, Genetics and molecular research : GMR.

[22]  G. Wilson Hypoxia and prognosis: the oxygen tension mounts. , 2007, Frontiers in bioscience : a journal and virtual library.

[23]  H. J. O’neill,et al.  Volatile organic compounds in exhaled air from patients with lung cancer. , 1985, Clinical chemistry.

[24]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[25]  T. Risby,et al.  Current status of clinical breath analysis , 2005 .

[26]  Kirsten Peters,et al.  Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. , 2008, International journal of oncology.

[27]  Wolfgang Losert,et al.  Understanding health and disease with multidimensional single-cell methods , 2013, Journal of physics. Condensed matter : an Institute of Physics journal.

[28]  T. Risby Critical issues for breath analysis , 2008 .

[29]  David Smith,et al.  Quantification of acetaldehyde released by lung cancer cells in vitro using selected ion flow tube mass spectrometry. , 2003, Rapid communications in mass spectrometry : RCM.

[30]  Breath volatile analysis from patients diagnosed with harmful drinking, cirrhosis and hepatic encephalopathy: a pilot study , 2013, Metabolomics.

[31]  Bradford G. Stone,et al.  Effect of regulating cholesterol biosynthesis on breath isoprene excretion in men , 1993, Lipids.

[32]  P. Vaupel,et al.  Tumor hypoxia and malignant progression. , 2009, Methods in enzymology.

[33]  Bogusław Buszewski,et al.  Human exhaled air analytics: biomarkers of diseases. , 2007, Biomedical chromatography : BMC.

[34]  T. Hintze,et al.  Cytochrome P-450 oxidation of alkanes originating as scission products during lipid peroxidation. , 1984, Xenobiotica; the fate of foreign compounds in biological systems.

[35]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.

[36]  S. Loft,et al.  Cancer risk and oxidative DNA damage in man , 1996, Journal of Molecular Medicine.

[37]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[38]  Tomas Mikoviny,et al.  Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. , 2009, Anticancer research.

[39]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[40]  Wolfram Miekisch,et al.  From highly sophisticated analytical techniques to life-saving diagnostics: Technical developments in breath analysis , 2006 .

[41]  D. Crowther,et al.  Cancer—Principles and Practice of Oncology. V , 1982, British Journal of Cancer.

[42]  J. Pouysségur,et al.  Oxygen, a source of life and stress , 2007, FEBS letters.

[43]  A. B. Robinson,et al.  Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Phillips,et al.  Effect of age on the breath methylated alkane contour, a display of apparent new markers of oxidative stress. , 2000, The Journal of laboratory and clinical medicine.

[45]  Sven Rahmann,et al.  IMS2 - An integrated medical software system for early lung cancer detection using ion mobility spectrometry data of human breath , 2007, J. Integr. Bioinform..

[46]  Robert G. Hahn,et al.  Role of Variability in Explaining Ethanol Pharmacokinetics , 2003, Clinical pharmacokinetics.

[47]  Anton Amann,et al.  Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas , 2007 .

[48]  M. Phillips,et al.  Breath tests in medicine. , 1992, Scientific American.

[49]  Anton Amann,et al.  Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. , 2011, Cancer biomarkers : section A of Disease markers.

[50]  E. Wouters,et al.  Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[51]  T. H. Risby CURRENT STATUS OF CLINICAL BREATH ANALYSIS , 2005 .

[52]  M. Ledochowski, B. Widner, C. Murr, B. Sperner-Unt Fructose Malabsorption is Associated with Decreased Plasma Tryptophan , 2001 .

[53]  S. Loft,et al.  Cancer risk and oxidative DNA damage in man , 1997, Journal of Molecular Medicine.

[54]  D. Fuchs,et al.  Fructose malabsorption is associated with decreased plasma tryptophan. , 2001, Scandinavian journal of gastroenterology.

[55]  A. Jemal,et al.  Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[56]  Padma Maruvada,et al.  Metabolomics in biomarker discovery: future uses for cancer prevention. , 2008, Future oncology.

[57]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[58]  Ping Wang,et al.  Detection of Lung Cancer with Volatile Organic Biomarkers in Exhaled Breath and Lung Cancer Cells , 2009 .

[59]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[60]  S. Batra,et al.  Lipid peroxidation, free radical production and antioxidant status in breast cancer , 2004, Breast Cancer Research and Treatment.

[61]  Minro Watanabe,et al.  Polymorphic CYP genes and disease predisposition--what have the studies shown so far? , 1998, Toxicology letters.

[62]  M. Phillips,et al.  Variation in volatile organic compounds in the breath of normal humans. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[63]  Solid phase microextraction for analysis of alkanes and aromatic hydrocarbons in human breath. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[64]  Peter Vaupel,et al.  Tumor microenvironmental physiology and its implications for radiation oncology. , 2004, Seminars in radiation oncology.

[65]  Eko Supriyanto,et al.  Tangible nanocomposites with diverse properties for heart valve application , 2015, Science and technology of advanced materials.

[66]  Ping Wang,et al.  A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis , 2007, Cancer.

[67]  G. Kalna,et al.  Metabolic Profiling of Hypoxic Cells Revealed a Catabolic Signature Required for Cell Survival , 2011, PloS one.

[68]  Yu. A. Zolotov Breath Analysis , 2005 .

[69]  N. Bellance,et al.  Metabolomics for mitochondrial and cancer studies. , 2011, Biochimica et biophysica acta.

[70]  R. Jain Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. , 2002, Seminars in oncology.

[71]  R. Wenger,et al.  Cellular adaptation to hypoxia: O2‐sensing protein hydroxylases, hypoxia‐inducible transcription factors, and O2‐regulated gene expression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[72]  Kohji Mitsubayashi,et al.  Bioelectronic sniffers for ethanol and acetaldehyde in breath air after drinking. , 2005, Biosensors & bioelectronics.

[73]  J. Lindon,et al.  'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[74]  L. Bianchi,et al.  Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study , 2005, Respiratory research.

[75]  David Smith,et al.  A longitudinal study of ethanol and acetaldehyde in the exhaled breath of healthy volunteers using selected-ion flow-tube mass spectrometry. , 2006, Rapid communications in mass spectrometry : RCM.

[76]  A. Hansel,et al.  Acetonitrile and benzene in the breath of smokers and non-smokers investigated by proton transfer reaction mass spectrometry (PTR-MS) , 1995 .

[77]  J. Lindon,et al.  Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.